Toggle Health Problems and D

Vitamin D2 not help – again ( T1 diabetes– which has been helped by D3) – Jan 2022

Ergocalciferol in New-onset Type 1 Diabetes: A Randomized Controlled Trial

Journal of the Endocrine Society, Vol 6, Issue 1, Jan 2022, https://doi.org/10.1210/jendso/bvab179
Benjamin Udoka Nwosu, Sadichchha Parajuli, Gabrielle Jasmin, Jody Fleshman, Rohit B Sharma, Laura C Alonso, Austin F Lee, Bruce A Barton

The effect of the anti-inflammatory and immunomodulatory actions of vitamin D on the duration of partial clinical remission (PR) in youth with type 1 diabetes (T1D) is unclear.

This work aimed to determine the effect of adjunctive ergocalciferol on residual β-cell function (RBCF) and PR in youth with newly diagnosed T1D who were maintained on a standardized insulin treatment protocol. The hypothesis was that ergocalciferol supplementation increases RBCF and prolongs PR.

A 12-month, randomized, double-blind, placebo-controlled trial was conducted of 50,000 IU of ergocalciferol per week for 2 months, and then once every 2 weeks for 10 months, vs placebo in 36 individuals aged 10 to 21 years, with T1D of less than 3 months and a stimulated C-peptide (SCP) level greater than or equal to 0.2 nmol/L (≥ 0.6 ng/mL). The ergocalciferol group had 18 randomly assigned participants (10 male/8 female), mean age 13.3 ± 2.8 years, while the control group had 18 participants (14 male/4 female), aged 14.3 ± 2.9 years.

The ergocalciferol treatment group had statistically significantly higher serum 25-hydroxyvitamin D at 6 months (P = .01) and 9 months (P = .02) than the placebo group. At 12 months, the ergocalciferol group had a statistically significantly lower serum tumor necrosis factor α (TNF-α) concentration (P = .03). There were no statistically significant differences between the groups at each time point from baseline to 12 months for SCP concentration (P = .08), glycated hemoglobin A1c (HbA1c) (P = .09), insulin dose–adjusted A1c (IDAA1c), or total daily dose of insulin. Temporal trends for rising HbA1c (P = .04) and IDAA1c (P = .02) were statistically significantly blunted in the ergocalciferol group.

Ergocalciferol statistically significantly reduced serum TNF-α concentration and the rates of increase both in A1c and IDAA1c, suggesting a protection of RBCF and PR in youth with newly diagnosed T1D.

Vitamin D2 should never be used for any mammal - 2006

VitaminDWiki - Overview Diabetes and vitamin D contains:

  • Diabetes is 5X more frequent far from the equator
  • Children getting 2,000 IU of vitamin D are 8X less likely to get Type 1 diabetes
  • Obese people get less sun / Vitamin D - and also vitamin D gets lost in fat
  • Sedentary people get less sun / Vitamin D
  • Worldwide Diabetes increase has been concurrent with vitamin D decrease and air conditioning
  • Elderly get 4X less vitamin D from the same amount of sun
        Elderly also spend less time outdoors and have more clothes on
  • All items in category Diabetes and Vitamin D 531 items: both Type 1 and Type 2

Vitamin D appears to both prevent and treat diabetes

Number of articles in both categories of Diabetes and:
'This list is automatically updated''

  • Dark Skin 24;   Intervention 56;   Meta-analysis 38;   Obesity 35;  Pregnancy 43;   T1 (child) 39;  Omega-3 11;  Vitamin D Receptor 24;  Genetics 12;  Magnesium 27    Click here to see details

Some Diabetes studies

50 ng of Vitamin D fights Diabetes

T1 Diabetes


Diabetes, Metabolic Syndrome and Magnesium - many studies
- - - - - - - - - - - - - - - - - -
Type 1 Diabetes is prevented and treated by Vitamin D – review of 16 studies – Sept 2019

Perhaps they used D2 because that is the only form of D that can be prescribed in their country

Created by admin. Last Modification: Friday December 17, 2021 18:30:43 GMT-0000 by admin. (Version 2)